[^195mPt]Cisplatin for lung cancer imaging: a pilot study.

IF 3.1 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

EJNMMI Research Pub Date : 2025-07-16 DOI:10.1186/s13550-025-01281-z

Denise S Hoogenkamp, Berlinda J de Wit-van der Veen, Jeske Hendriksen, Karlijn van der Schilden, Josefine A M Nanne, José S A Belderbos, Maddalena M Rossi, Martien P J Mooijer, Uta Funke, N Harry Hendrikse, Wouter V Vogel, Else A Aalbersberg

{"title":"[195mPt]Cisplatin for lung cancer imaging: a pilot study.","authors":"Denise S Hoogenkamp, Berlinda J de Wit-van der Veen, Jeske Hendriksen, Karlijn van der Schilden, Josefine A M Nanne, José S A Belderbos, Maddalena M Rossi, Martien P J Mooijer, Uta Funke, N Harry Hendrikse, Wouter V Vogel, Else A Aalbersberg","doi":"10.1186/s13550-025-01281-z","DOIUrl":null,"url":null,"abstract":"Background: Radiolabeled [195mPt]cisplatin has been developed as a tool to determine the biodistribution of cisplatin in vivo through SPECT imaging and possibly aid in patient-selection. This feasibility study aimed to evaluate the (radiation) safety, biodistribution, and image quality of [195mPt]cisplatin SPECT/CT in patients with non-small cell lung cancer (NSCLC). [195mPt]Cisplatin was produced under GMP standards. Six patients received 100 MBq [195mPt]cisplatin in their second or third week of chemoradiation therapy. Planar and SPECT/CT imaging were acquired at 1.5, 48, 120 and 168 h post-administration. Segmentation on SPECT for biodistribution and dosimetry was achieved using TotalSegmentator in 3DSlicer, and organ specific time-activity curves were generated through a mono-exponential curve fit. Effective and absorbed doses were obtained with S-values from IDAC-Dose 2.1. Toxicity was assessed using CTCAE criteria.Results: Six NSCLC patients received 100.9 ± 3.3 MBq [195mPt]cisplatin at a radioactivity concentration of 11.1 ± 4.9 MBq/mL. No adverse events above grade 2 were observed. [195mPt]Cisplatin had a long retention time with an effective half-life of 74.8 h. Uptake was highest in the liver and kidneys, which also resulted in the highest absorbed dose at 48.6 ± 7.9 mGy and 38.4 ± 7.3 mGy, respectively. Tumor uptake was similar to blood, with a ratio of 1.0 ± 0.05.Conclusion: [195mPt]Cisplatin is safe to use for imaging in patients with NSCLC when injecting 100 MBq, reaching a mean effective dose of 14.6 ± 1.5 mSv. The image quality of [195mPt]cisplatin was suitable for SPECT imaging and quantification. Tumor uptake was similar to blood.Trial registration: CCMO, NL74272.031.21. Registered 28 January 2022, https://www.onderzoekmetmensen.nl/nl/trial/55147 .","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"87"},"PeriodicalIF":3.1000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267755/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-025-01281-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Radiolabeled [^195mPt]cisplatin has been developed as a tool to determine the biodistribution of cisplatin in vivo through SPECT imaging and possibly aid in patient-selection. This feasibility study aimed to evaluate the (radiation) safety, biodistribution, and image quality of [^195mPt]cisplatin SPECT/CT in patients with non-small cell lung cancer (NSCLC). [^195mPt]Cisplatin was produced under GMP standards. Six patients received 100 MBq [^195mPt]cisplatin in their second or third week of chemoradiation therapy. Planar and SPECT/CT imaging were acquired at 1.5, 48, 120 and 168 h post-administration. Segmentation on SPECT for biodistribution and dosimetry was achieved using TotalSegmentator in 3DSlicer, and organ specific time-activity curves were generated through a mono-exponential curve fit. Effective and absorbed doses were obtained with S-values from IDAC-Dose 2.1. Toxicity was assessed using CTCAE criteria.

Results: Six NSCLC patients received 100.9 ± 3.3 MBq [^195mPt]cisplatin at a radioactivity concentration of 11.1 ± 4.9 MBq/mL. No adverse events above grade 2 were observed. [^195mPt]Cisplatin had a long retention time with an effective half-life of 74.8 h. Uptake was highest in the liver and kidneys, which also resulted in the highest absorbed dose at 48.6 ± 7.9 mGy and 38.4 ± 7.3 mGy, respectively. Tumor uptake was similar to blood, with a ratio of 1.0 ± 0.05.

Conclusion: [^195mPt]Cisplatin is safe to use for imaging in patients with NSCLC when injecting 100 MBq, reaching a mean effective dose of 14.6 ± 1.5 mSv. The image quality of [^195mPt]cisplatin was suitable for SPECT imaging and quantification. Tumor uptake was similar to blood.

Trial registration: CCMO, NL74272.031.21. Registered 28 January 2022, https://www.onderzoekmetmensen.nl/nl/trial/55147 .

Abstract Image

查看原文本刊更多论文

[195mPt]顺铂治疗肺癌影像学的初步研究。

背景：放射性标记[195mPt]顺铂已发展成为一种工具，通过SPECT成像确定体内顺铂的生物分布，并可能有助于患者选择。本可行性研究旨在评估[195mPt]顺铂SPECT/CT在非小细胞肺癌（NSCLC）患者中的（辐射）安全性、生物分布和图像质量。【195mPt】顺铂按GMP标准生产。6例患者在放化疗的第二周或第三周接受100 MBq [195mPt]顺铂治疗。分别于给药后1.5、48、120和168 h进行平面和SPECT/CT成像。利用3DSlicer中的TotalSegmentator对SPECT进行生物分布和剂量的分割，并通过单指数曲线拟合生成器官特定时间-活性曲线。有效剂量和吸收剂量用IDAC-Dose 2.1的s值计算。采用CTCAE标准评估毒性。结果：6例NSCLC患者接受了100.9±3.3 MBq [195mPt]顺铂治疗，放射性浓度为11.1±4.9 MBq/mL。未观察到2级以上不良事件。[195mPt]顺铂保留时间长，有效半衰期为74.8 h，肝脏和肾脏吸收最高，吸收剂量最高，分别为48.6±7.9 mGy和38.4±7.3 mGy。肿瘤摄取与血液相似，比值为1.0±0.05。结论：[195mPt]顺铂在注射100 MBq时用于NSCLC患者影像学是安全的，平均有效剂量为14.6±1.5 mSv。[195mPt]顺铂的图像质量适合SPECT成像和定量。肿瘤摄取与血液相似。试验注册：CCMO， NL74272.031.21。2022年1月28日注册，网址：https://www.onderzoekmetmensen.nl/nl/trial/55147。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-

CiteScore

5.90

自引率

3.10%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.